Seganserin (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name; developmental code name R-56413) is a selective serotonin 5-HT2 receptor antagonist which was studied for the treatment of insomnia and anxiety but was never marketed. It acts as a dual serotonin 5-HT2A and 5-HT2C receptor antagonist. The drug blocks the head-twitch response induced by serotonin precursor 5-hydroxytryptophan (5-HTP) and the psychedelic drug mescaline in rodents. It has been found to enhance slow wave sleep (SWS) in clinical studies. The drug's time to peak levels is 1 hour and its elimination half-life is 26 hours. Seganserin reached phase 2 clinical trials prior to the discontinuation of its development. It was first described in the scientific literature by 1985.
See also Serotonin 5-HT2A receptor antagonist List of investigational insomnia drugs
References


